Thrivent Financial for Lutherans Has $2.97 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Thrivent Financial for Lutherans cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 44.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,802 shares of the company’s stock after selling 20,775 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Neurocrine Biosciences were worth $2,973,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences during the second quarter valued at about $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences in the first quarter valued at $32,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences in the second quarter worth $35,000. Finally, Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Up 0.6 %

Shares of NBIX opened at $127.91 on Wednesday. The stock has a market cap of $12.95 billion, a P/E ratio of 34.29 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 1 year low of $110.52 and a 1 year high of $157.98. The stock’s 50-day moving average price is $118.83 and its two-hundred day moving average price is $131.74.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NBIX shares. HC Wainwright reaffirmed a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Citigroup lifted their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Royal Bank of Canada dropped their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Raymond James restated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Jefferies Financial Group upped their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.